Preclinical DMPK/ADME Services
At Ace Therapeutics, we understand the unique challenges of developing therapies for Alzheimer's disease (AD). Our preclinical Drug Metabolism and Pharmacokinetics (DMPK) and Absorption, Distribution, Metabolism, Excretion (ADME) services are tailored to address the complexities of neurodegenerative drug candidates, ensuring your molecules move swiftly from discovery to clinical trials.
Alzheimer's drug candidates face critical hurdles, such as crossing the blood-brain barrier (BBB), mitigating neurotoxicity, and navigating species-specific metabolic pathways. Failure to optimize pharmacokinetics (PK) and pharmacodynamics (PD) early often leads to costly late-stage attrition. Our services bridge this gap by combining cutting-edge technologies with deep expertise in CNS drug development.
Overcoming the BBB is a make-or-break factor for Alzheimer's therapeutics. We employ advanced models to evaluate drug permeability.
Our ADME studies provide actionable insights into your compound's behavior.
Leverage machine learning to accelerate candidate selection.
Early intervention is key in AD management. We employ biomarker-based approaches to assess drug exposure in preclinical models, linking pharmacokinetic data to pharmacodynamic outcomes such as amyloid plaque reduction or synaptic preservation.
From 3D neurospheroids to transgenic mouse models, our platform replicates AD pathology to test drug behavior under physiologically relevant conditions. These models help identify off-target effects and optimize dosing regimens early in development.
To address the multifaceted nature of Alzheimer's R&D, we deploy innovative platforms.
| Technology | Application |
| Organ-on-chip BBB models | Real-time monitoring of drug permeation and neuroinflammation effects. |
| PET imaging | Non-invasive tracking of CNS drug distribution. |
| High-throughput LC-MS/MS | Rapid bioanalytical method development for tau-targeting molecules. |
| Microdosing trials | Early human PK data for lead prioritization. |
At Ace Therapeutics, we transform preclinical challenges into opportunities. By prioritizing CNS-specific DMPK/ADME insights, we help you derisk candidates, refine formulations, and unlock the full potential of your AD therapeutics. Contact us to today to discuss how our expertise can elevate your research pipeline.
How do you customize ADME studies for Alzheimer's-specific targets like tau or amyloid-beta
We integrate target-binding assays (e.g., SPR, ITC) with traditional ADME workflows to evaluate how protein aggregation impacts drug distribution and clearance.
What models do you use for BBB permeability testing
Our tiered approach includes PAMPA-BBB for early screening, 3D brain spheroids for mechanistic insights, and in vivo transgenic models for final validation.
Can you support orphan Alzheimer's indications with limited compound availability
Yes. Our microdosing and microsampling protocols require minimal material, ideal for rare disease programs.
How long does a typical preclinical DMPK package take
Turnaround times range from 6 weeks to 6 months.
Our products and services are for research use only and can not be used for diagnostic or other purposes.
Make Order
Experimental Scheme
Implementation
Conclusion
Ace Therapeutics is a specialized team of scientists and technical professionals committed to working closely with clients worldwide. We offer comprehensive preclinical testing solutions to support the development of novel therapies and medications across a range of disease areas.
Ace Therapeutics boasts a team of highly committed and skilled researchers dedicated to delivering innovative preclinical contract research solutions.
We provide tailored preclinical services designed to streamline your research process and advance promising concepts into actionable insights, ensuring efficient progress in drug development.